scholarly journals Safety and Efficacy of Indigenous Equine Antithymocyte Globulin Along with Cyclosporine in Subjects with Acquired Aplastic Anemia

2014 ◽  
Vol 31 (2) ◽  
pp. 174-179 ◽  
Author(s):  
M. B. Agarwal ◽  
Farah Jijina ◽  
Sandip Shah ◽  
Pankaj Malhotra ◽  
Sharat Damodar ◽  
...  
Keyword(s):  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Safety And Efficacy

The use of antithymocyte globulin in the treatment of severe aplastic anemia in children

1982 ◽  
Vol 100 (2) ◽  
pp. 307-311 ◽  
Author(s):  
Mitchell S. Cairo ◽  
Robert L. Baehner
Keyword(s):  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Severe Aplastic Anemia

scholarly journals A retrospective comparison of cyclophosphamide plus antithymocyte globulin with cyclophosphamide plus busulfan as the conditioning regimen for severe aplastic anemia

2009 ◽  
Vol 42 (3) ◽  
pp. 244-250 ◽  
Author(s):  
L.V.M. Ommati ◽  
C.A. Rodrigues ◽  
A.R. Silva ◽  
L.P. Silva ◽  
M.L.L.F. Chaufaille ◽  
...  
Keyword(s):  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Conditioning Regimen ◽  
Severe Aplastic Anemia ◽  
Retrospective Comparison

scholarly journals Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia

Haematologica ◽  
2015 ◽  
Vol 100 (9) ◽  
pp. e345-e347 ◽  
Author(s):  
D. V. Cle ◽  
E. H. Atta ◽  
D. S. P. Dias ◽  
C. B. L. Lima ◽  
M. Bonduel ◽  
...  
Keyword(s):  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Initial Therapy ◽  
Rabbit Antithymocyte Globulin

Reduced dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia

2013 ◽  
Vol 17 (4) ◽  
pp. 387-393 ◽  
Author(s):  
Nack-Gyun Chung ◽  
Jae Wook Lee ◽  
Pil-Sang Jang ◽  
Dae-Chul Jeong ◽  
Bin Cho ◽  
...  
Keyword(s):  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Severe Aplastic Anemia ◽  
Reduced Dose

scholarly journals Outcome of children with severe acquired aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine A

2014 ◽  
Vol 90 (5) ◽  
pp. 523-527 ◽  
Author(s):  
Marlene Pereira Garanito ◽  
Jorge David Aivazoglou Carneiro ◽  
Vicente Odone Filho ◽  
Phillip Scheinberg
Keyword(s):  
Aplastic Anemia ◽  
Cyclosporine A ◽  
Antithymocyte Globulin ◽  
Rabbit Antithymocyte Globulin

scholarly journals Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia

Blood ◽  
1992 ◽  
Vol 79 (10) ◽  
pp. 2540-2546 ◽  
Author(s):  
E Gluckman ◽  
H Esperou-Bourdeau ◽  
A Baruchel ◽  
M Boogaerts ◽  
J Briere ◽  
...  
Keyword(s):  
Partial Response ◽  
Aplastic Anemia ◽  
Antithymocyte Globulin ◽  
Bone Marrow Failure ◽  
Randomized Study ◽  
Alternative Therapy ◽  
Survival Rates ◽  
Severe Aplastic Anemia ◽  
Actuarial Survival ◽  
Significant Difference

Abstract We report the results of a randomized multicenter study comparing the efficacy of antithymocyte globulin (ATG) with that of cyclosporin A (CsA) as first-line therapy for severe aplastic anemia (SAA). Patients were randomized to receive ATG and prednisone (PDN) or CsA; hematologic response and toxicity were compared. At 3-month evaluation, patients who had no or minimal response received the alternative therapy to assess the value of a sequential immunosuppressive therapy for treatment of severe aplastic anemia. One hundred nineteen patients were randomized; 25 were excluded, of whom 3 were misdiagnosed and 22 did not follow the cross-over protocol. Ninety-four patients were analyzed; 46 received CsA, and 48 received ATG-PDN. The actuarial survival was 66.7%, with a median follow-up time of 19 months. There was no significant difference in survival between the groups with, at 3 months, an actuarial survival of 88% in the CsA group and 75% in the ATG group (NS); at 12 months, it was 70% in the CsA group and 64% in the ATG group (NS). The percentage of complete and partial response was 11.6% and 16%, respectively, at 3 months, and 31.6% and 30%, respectively, at 12 months (NS). The main prognostic factor was the absolute neutrophil count (ANC) at entry: Patients with ANC less than 0.2 x 10(9)/L had a significantly lower survival as compared with patients with more than 0.2 x 10(9)/L ANC (P = .0001). At 12 months, 62 evaluable patients were alive, with a complete or partial response in 36 patients. Patients who had responded to the first treatment had a better recovery of bone marrow failure than those who had sequential immunosuppression. The main complication was infection, which was more often observed and more often lethal during ATG and PDN therapy. In this study, initial treatment of SAA with either CsA or ATG-PDN followed by cross-over therapy for nonresponders produced comparable response and survival rates.

scholarly journals Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia

Blood ◽  
1994 ◽  
Vol 84 (3) ◽  
pp. 941-949 ◽  
Author(s):  
R Storb ◽  
R Etzioni ◽  
C Anasetti ◽  
FR Appelbaum ◽  
CD Buckner ◽  
...  
Keyword(s):  
Survival Rate ◽  
Aplastic Anemia ◽  
Graft Rejection ◽  
Antithymocyte Globulin ◽  
Chronic Gvhd ◽  
Immunosuppressive Agents ◽  
Buffy Coat ◽  
Marrow Graft ◽  
Actuarial Survival ◽  
Actuarial Survival Rate

Abstract Graft rejection has been a problem after marrow grafts for patients with aplastic anemia who were conditioned with cyclophosphamide (CY). Rejection lessened when patients were given the marrow donor“s peripheral blood buffy-coat cells in addition to the marrow, but this result was achieved at the price of more chronic graft-versus-host disease (GVHD). Results with second transplants suggested that CY alternating with antithymocyte globulin (ATG) was more immunosuppressive than CY alone. Therefore, the current study explored CY and ATG without buffy-coat cell transfusions in 39 patients with aplastic anemia given marrow transplants from HLA-identical family members (siblings in 38 cases, father in 1 case). We hoped both to minimize the risks of graft rejection and of chronic GVHD and to improve survival. Patients were 2 to 52 years of age (median, 24.5); 87% had received previous transfusions, and 41% had therapy with immunosuppressive agents before transplant. They were administered four daily doses of CY (total, 200 mg/kg) alternating with three doses of ATG (total, 90 mg/kg) followed by an HLA-identical marrow graft. Methotrexate and cyclosporine were administered to prevent GVHD. Two patients rejected their grafts (5%), and both were successfully retransplanted. Acute (grade 2 or 3) GVHD occurred in 15% and chronic GVHD in 34% of patients. The actuarial survival rate at 3 years was 92%, which compares favorably to the 72% survival rate in 39 historical patients who were matched with current patients for age and risk factors for rejection and GVHD. CY/ATG is a well-tolerated and effective conditioning program for marrow grafting in aplastic anemia that, when combined with GVHD prevention by methotrexate/cyclosporine, results in excellent survival.

Sign in / Sign up

Export Citation Format

Share Document